Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
1.110
+0.040 (3.74%)
At close: Nov 21, 2024, 4:00 PM
1.100
-0.010 (-0.90%)
After-hours: Nov 21, 2024, 4:35 PM EST
Immunic Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
77
Market Cap
99.99M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Coherus BioSciences | 304.34M |
PetMed Express | 259.34M |
Karyopharm Therapeutics | 148.44M |
FONAR | 102.01M |
Generation Bio Co. | 18.58M |
Coya Therapeutics | 9.55M |
IMUX News
- 8 days ago - Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology - PRNewsWire
- 12 days ago - Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 21 days ago - Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update - PRNewsWire
- 23 days ago - Immunic to Participate in Industry, Scientific and Investor Conferences in November - PRNewsWire
- 4 weeks ago - Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis - PRNewsWire
- 2 months ago - Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis - PRNewsWire
- 2 months ago - Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome - PRNewsWire